Insider Selling: HealthEquity, Inc. (NASDAQ:HQY) Director Sells 32,500 Shares of Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Evelyn S. Dilsaver sold 32,500 shares of the stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total value of $2,576,925.00. Following the completion of the transaction, the director now owns 32,123 shares of the company’s stock, valued at $2,547,032.67. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

HealthEquity Trading Up 2.4 %

NASDAQ:HQY opened at $81.63 on Friday. The company has a current ratio of 4.76, a quick ratio of 4.93 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $7.00 billion, a PE ratio of 127.55, a price-to-earnings-growth ratio of 1.34 and a beta of 0.53. The firm’s 50 day moving average is $79.90 and its 200 day moving average is $73.31. HealthEquity, Inc. has a 12 month low of $48.86 and a 12 month high of $84.49.

Analysts Set New Price Targets

HQY has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their target price on HealthEquity from $81.00 to $73.00 and set an “overweight” rating for the company in a research report on Friday, December 1st. Barrington Research reiterated an “outperform” rating and set a $100.00 price target on shares of HealthEquity in a report on Friday, March 22nd. Raymond James increased their price target on HealthEquity from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, December 13th. BTIG Research increased their price target on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Finally, Bank of America increased their price target on HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $92.55.

Institutional Investors Weigh In On HealthEquity

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of HealthEquity by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 8,619,499 shares of the company’s stock worth $571,473,000 after purchasing an additional 104,084 shares during the period. Goldman Sachs Group Inc. grew its position in shares of HealthEquity by 24.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,129,634 shares of the company’s stock valued at $74,895,000 after purchasing an additional 223,428 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of HealthEquity by 6.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 48,019 shares of the company’s stock valued at $3,184,000 after purchasing an additional 2,712 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of HealthEquity during the 4th quarter valued at $1,475,000. Finally, Public Employees Retirement System of Ohio grew its position in shares of HealthEquity by 14.3% during the 4th quarter. Public Employees Retirement System of Ohio now owns 102,196 shares of the company’s stock valued at $6,776,000 after purchasing an additional 12,765 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.